Biomodal (previously Cambridge Epigenetix (CEGX)) is a life sciences tools and analytics company, founded in 2012, expanding the dimensions of genetic discovery and genome sequencing through a proprietary technology platform that has the potential to deliver step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.  This approach brings closer the day when advanced medicines, diagnostics, and personalized treatments become a reality for all.

The Biomodal platform, extends the information content of sequencing by unambiguously identifying five letters of DNA – four genetic bases (A-T-C-G) plus methylated cytosine (5mC or 5hmC).  This information is captured at single base resolution from very small amounts of DNA, and with an accuracy that exceeds other known methods.  This approach can significantly reduce sequencing costs whilst preserving complexity, facilitating rapid and lower cost data analysis.

Epigenetic marks are a vital source of biological information to enable the next generation of diagnostics including those for early cancer detection.  Biomodal is developing further technology platforms supported by their extensive IP portfolio.

In late 2021, the JIMCO Life Sciences Fund participated in Biomodal’s (previously Cambridge Epigenetix) US$ 88 million Series D funding round.

Visit: Biomodal